Vulcan Value Partners LLC Grows Stock Holdings in IQVIA Holdings Inc. $IQV

Vulcan Value Partners LLC increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.7% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 259,856 shares of the medical research company’s stock after buying an additional 11,755 shares during the quarter. IQVIA makes up about 1.5% of Vulcan Value Partners LLC’s investment portfolio, making the stock its 15th largest position. Vulcan Value Partners LLC’s holdings in IQVIA were worth $50,209,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of IQV. Korea Investment CORP bought a new stake in IQVIA during the 2nd quarter valued at approximately $13,918,000. Deutsche Bank AG bought a new position in IQVIA in the 2nd quarter worth approximately $143,074,000. BlackRock Inc. bought a new position in IQVIA in the 2nd quarter worth approximately $2,811,292,000. Focus Partners Advisor Solutions LLC purchased a new stake in IQVIA during the 2nd quarter valued at approximately $976,000. Finally, Pallas Capital Advisors LLC bought a new stake in shares of IQVIA during the second quarter valued at approximately $1,552,000. 89.62% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, insider Keriann Cherofsky sold 558 shares of IQVIA stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares in the company, valued at approximately $732,932.69. The trade was a 15.73% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider James G. Berkshire sold 2,668 shares of the business’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $261.33, for a total value of $697,228.44. Following the transaction, the insider directly owned 10,890 shares in the company, valued at approximately $2,845,883.70. This represents a 19.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 15,581 shares of company stock worth $3,796,021. 1.70% of the stock is currently owned by company insiders.

IQVIA Price Performance

Shares of NYSE IQV traded down $8.28 during mid-day trading on Tuesday, hitting $259.49. 1,381,305 shares of the company’s stock traded hands, compared to its average volume of 1,734,320. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $271.80. The company’s 50-day moving average is $233.34 and its two-hundred day moving average is $194.19. The company has a market capitalization of $42.71 billion, a P/E ratio of 32.19, a PEG ratio of 2.29 and a beta of 1.18.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, topping the consensus estimate of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The company had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same quarter last year, the business posted $2.81 earnings per share. The firm’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of IQVIA from $225.00 to $285.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. HSBC reiterated a “buy” rating and issued a $240.00 price target on shares of IQVIA in a report on Monday, July 6th. Mizuho increased their price objective on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. BMO Capital Markets raised their price objective on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Finally, Robert W. Baird lifted their target price on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $243.62.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.